First Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary; MTA-SE NAP, Brain Metastasis Research Group, Hungarian Academy of Sciences, Second Department of Pathology, Semmelweis University, Budapest, Hungary; Department of Pulmonology, Semmelweis University, Budapest, Hungary; Department of Physics of Complex Systems, Eötvös Loránd University, Budapest, Hungary; Institute of Behavioural Sciences, Semmelweis University, Budapest, Hungary; Department of Neurooncology, National Institute of Clinical Neurosciences, Budapest, Hungary; Department of Radiology, National Institute of Clinical Neurosciences, Budapest, Hungary; Sixth Department of Pulmonology, National Korányi Institute of Pulmonology, Budapest, Hungary; Hungarian Academy of Sciences-Semmelweis University, Molecular Oncology Research Unit, Budapest, Hungary; Department of Tumor Biology, National Korányi Institute of Pulmonology-Semmelweis University, Budapest, Hungary; Department of Thoracic Surgery, National Institute of Oncology-Semmelweis University, Budapest, Hungary; Division of Thoracic Surgery, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Children's Hospital Informatics Program at the Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts, USA; Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Lyngby, Denmark; CRUK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, UK; Francis Crick Institute, London, UK.
Neuro Oncol. 2017 Aug 1;19(8):1058-1067. doi: 10.1093/neuonc/now309.
Management of lung cancer patients who suffer from brain metastases represents a major challenge. Considering the promising results with immune checkpoint inhibitor treatment, evaluating the status of immune cell (IC) infiltrates in the prognosis of brain metastasis may lead to better therapeutic strategies with these agents. The aim of this study was to characterize the distribution of ICs and determine the expression of the checkpoint molecules programmed death protein 1 (PD-1) and its ligand, PD-L1, in brain metastasis of lung adenocarcinoma (LUAD) patients and to analyze their clinicopathological correlations.
We determined the presence of peritumoral mononuclear cells (mononuclear ring) and the density of intratumoral stromal mononuclear cells on brain metastasis tissue sections of 208 LUAD patients. PD-L1/PD-1 expressions were analyzed by immunohistochemistry.
Mononuclear rings were significantly associated with better survival after brain metastasis surgery. Cases with massive stromal IC infiltration also showed a tendency for better overall survival. Lower expression of PD-1 and PD-L1 was associated with better survival in patients who underwent surgery for the primary tumor and had multiple brain metastases. Steroid administration and chemotherapy appear not to influence the density of IC in brain metastasis.
This is the first study demonstrating the independent prognostic value of mononuclear rings in LUAD cases with brain metastasis. Our results also suggest that the density of tumor-associated ICs in addition to PD-L1 expression of tumor cells and ICs as well as PD-1 expression of ICs may hold relevant information for the appropriate selection of patients who might benefit from anti-PD-L1 or anti-PD-1 therapy.
肺癌伴脑转移患者的治疗是一个重大挑战。鉴于免疫检查点抑制剂治疗的良好效果,评估脑转移灶中免疫细胞(IC)浸润的状态可能会为这些药物的治疗策略提供更好的依据。本研究旨在描述肺癌脑转移患者脑转移灶中 IC 的分布,并确定程序性死亡蛋白 1(PD-1)及其配体 PD-L1 的表达情况,分析其与临床病理的相关性。
我们在 208 例肺腺癌(LUAD)脑转移患者的脑转移组织切片中检测了肿瘤周围单核细胞(单核环)和肿瘤内基质单核细胞的密度。通过免疫组化分析 PD-L1/PD-1 的表达。
单核环与脑转移手术后的生存时间显著相关。大量基质 IC 浸润的病例总生存率也有改善的趋势。在接受原发性肿瘤手术且有多发脑转移的患者中,PD-1 和 PD-L1 表达水平越低,生存时间越好。激素治疗和化疗似乎不会影响脑转移灶中 IC 的密度。
这是第一项证明单核环在 LUAD 伴脑转移患者中具有独立预后价值的研究。我们的研究结果还表明,肿瘤相关 IC 密度以及肿瘤细胞和 ICs 的 PD-L1 表达和 ICs 的 PD-1 表达可能为适当选择可能受益于抗 PD-L1 或抗 PD-1 治疗的患者提供相关信息。